Insider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells 75,000 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 75,000 shares of the firm's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $36.87, for a total value of $2,765,250.00. Following the completion of the sale, the chief executive officer now owns 4,948,447 shares in the company, valued at $182,449,240.89. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Neil Kumar also recently made the following trade(s):

• On Tuesday, February 25th, Neil Kumar sold 75,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $33.57, for a total transaction of $2,517,750.00.
• On Wednesday, February 19th, Neil Kumar sold 31,543 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.14, for a total value of $1,139,964.02.
• On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The stock was sold at an average price of $36.29, for a total value of $11,864,362.28.

BridgeBio Pharma Trading Down 1.5 %

BBIO stock traded down $0.54 on Monday, hitting $34.57. 2,651,438 shares of the company's stock traded hands, compared to its average volume of 2,196,733. The stock has a market cap of $6.57 billion, a price-to-earnings ratio of -12.13 and a beta of 1.07. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $39.47. The stock has a fifty day moving average of $34.28 and a 200-day moving average of $29.35.

Remove Ads

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to the consensus estimate of $4.04 million. On average, equities research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BBIO has been the subject of a number of analyst reports. Redburn Atlantic began coverage on BridgeBio Pharma in a research report on Monday. They set a "buy" rating and a $50.00 price target for the company. Citigroup lifted their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $95.00 target price on shares of BridgeBio Pharma in a research report on Friday, February 21st. HC Wainwright restated a "buy" rating and set a $49.00 price target on shares of BridgeBio Pharma in a research report on Thursday, February 13th. Finally, Scotiabank increased their price objective on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, BridgeBio Pharma presently has an average rating of "Moderate Buy" and a consensus price target of $52.64.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds have recently modified their holdings of BBIO. California State Teachers Retirement System raised its holdings in shares of BridgeBio Pharma by 6.8% during the fourth quarter. California State Teachers Retirement System now owns 115,655 shares of the company's stock valued at $3,174,000 after acquiring an additional 7,388 shares during the period. Jefferies Financial Group Inc. bought a new position in shares of BridgeBio Pharma in the fourth quarter valued at approximately $5,076,000. Mackenzie Financial Corp lifted its stake in shares of BridgeBio Pharma by 6.6% in the fourth quarter. Mackenzie Financial Corp now owns 9,505 shares of the company's stock worth $261,000 after buying an additional 592 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of BridgeBio Pharma during the 4th quarter worth $109,000. Finally, Frazier Life Sciences Management L.P. grew its stake in BridgeBio Pharma by 1.1% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company's stock valued at $104,285,000 after buying an additional 40,000 shares during the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.